LETTERS TO THE EDITOR

Primary sebaceous carcinoma of the lacrimal gland

EDITOR,—Sebaceous carcinoma is a rare primary neoplasm of the lacrimal gland and to the best of our knowledge only five cases have previously been reported.1-4 Sebaceous carcinoma of the orbit more commonly occurs as secondary invasion from the eyelid but may occur as metastatic spread from elsewhere in the body. We report a case of primary sebaceous carcinoma of the lacrimal gland and discuss the histological diagnosis and management of the disease.

CASE REPORT
A 35 year old woman was referred with a 6 month history of a gradually enlarging palpable mass arising in the left superotemporal orbit and causing painless and progressive diplopia. On examination she had a palpable, hard, fixed, left superotemporal orbital mass, a non-axial proptosis, and hypoglobus. The eyelids were normal. Examination of ocular motility revealed a restriction of left elevation. In addition, she was found to have an enlarged, painless ipsilateral preauricular lymph node. Computed tomograph (CT) and magnetic resonance imaging (MRI) scans showed the mass arising from the lacrimal gland (Fig 1).

A transseptal biopsy of the mass was performed and histological examination showed tissue infiltrated by carcinoma in which the neoplastic cells were large and contained prominent nucleoli. Many cells were vacuolated and contained lipid as confirmed by fat stains on unprocessed, fixed material. Immunohistochemistry revealed strongly positive staining for epithelial membrane antigen (EMA) but negative staining with antisera to cytokeratin, indicating the carcinoma to be of sebaceous origin (Fig 2). Metastatic spread from another primary site was excluded by general physical examination, chest x ray, mammography, and isotopic bone scan undertaken by an oncologist.

A left orbital exenteration with left superficial parotidectomy and excision of left cervical lymph nodes was performed. Histological examination of the exenteration specimen showed a 35 × 30 × 18 mm tumour arising in the region of the lacrimal gland, which had been entirely replaced by sebaceous carcinoma, with only a small focus of duc tally tissue being present at the margin of the tumour at one point. There was no involvement of the overlying periorbital skin, eyelid, or conjunctiva. The preauricular lymph node contained metastatic deposits, although her cervical lymph nodes were free from metastatic disease.

Postoperatively she underwent radiotherapy to the involved area and the orbit was allowed to granulate and re-epithelialise. Nine months after the surgery an isolated soft, mobile node was noted in the neck. This increased in size over 2 months and was found to be recurrent metastatic carcinoma on fine needle aspiration biopsy. Radical dissection of nodes in the neck confirmed involvement of 30–40 nodes and the patient received further radiotherapy. Six months after this, a swelling in the parotid region without lymphadenopathy again showed recurrent tumour. This lesion responded well to radiotherapy alone. Since then she has achieved good cosmesis with an orbital prosthesis and at the time of writing 3 years after original diagnosis she remains well with no signs of residual tumour.

COMMENT
Primary sebaceous carcinoma of the lacrimal gland possibly arising from heterotopic sebaceous tissue is extremely rare and must be differentiated from secondary invasion of the orbit by a primary eyelid tumour or metastatic spread from other areas of the body. The tumour is highly malignant and metastases to the preauricular and deep cervical lymph nodes occur early in the disease. Orbital exenteration is required and in addition parotidectomy and cervical lymphadenectomy combined with postoperative radiotherapy should be considered as part of the management.

The prognosis in previously reported patients was poor with local recurrences and metastases leading to death within 1 year. One previous patient survived to 22 months postoperatively.1 At the time of writing our patient is the first to show 3 year survival without evidence of further recurrence.

D BRISCOE
Department of Ophthalmology, Meir Hospital, Kfar Saba, Israel

S MAHMOOD
R BONSHIEK
Manchester Royal Eye Hospital, Oxford Road, Manchester M13 9WJ, UK

A JACKSON
Manchester Royal Infirmary

B LEATHERBARROW
Manchester Royal Eye Hospital

Correspondence to: Mr B Leatherbarrow, Royal Eye Hospital, Manchester M13 9WJ, UK
bolin@mighty-micro.co.uk
Accepted for publication 20 December 2000


months of age demonstrated persistent macular pigmentary changes in the left eye with elevation of the macula. Examination under anaesthesia was subsequently performed at 11 months of age which revealed normal anterior segment and clear crystalline lenses bilaterally. Funduscopic examination showed normal discs, vessels, and retinal periphery in both eyes. The right macula was normal without pigmentary abnormalities but the left macula revealed a raised choroidal lesion with an orange coloration and reactive pigmentary changes without retinal, detachment or subretinal fluid. On A and B-scan ultrasonogra phy the maximum height of the lesion was 2.1 mm and the reflectivity of the lesion was high. The clinical and ultrasonographic appearance was most consistent with the diagnosis of a circumscribed choroidal haemangiomai. Given the patient’s normal visual acuity and absence of subretinal fluid, observation was recommended in lieu of laser or radiation therapy. Follow up examination at 15 months of age revealed normal visual acuities without progression of the lesion.

**COMMENT**

The pathogenesis of haemangiomas remains largely unknown. Histologically, the hepatic and cutaneous haemangiomas are composed of vascular channels lined by endothelial cells as well as cells suggestive of pericytes. Similar histological characteristics are shared by circumscribed choroidal haemangiomai which consist of a mixture of small (capillary) or large (cavernous) vascular channels lined by endothelial cells separated by connective tissue septae.

Infantile hepatic and cutaneous haemangiomas show a high incidence of spontaneous regression and therapeutic measures are recommended only when associated conditions lead to morbidity. Although our patient’s hepatic lesion was clinically severe enough to warrant systemic or percutaneous injection of corticosteroids, the patient and his family refused oral corticosteroids and therefore refused systematic or percutaneous injection of corticosteroids. The patient was thus treated only by funduscopic observation. Echographic localisation of corticosteroid injection is recommended in corticosteroid refractory cases. We performed ultrasound guided corticosteroid injection into the choroidal lesion after funduscopic and echographic localisation of the lesion. The lesion was injected with 1 ml of 40 mg/ml triamcinolone acetonide mixed with 0.5 ml of 2% lignocaine (lidocaine) and 0.5 ml of 0.5% adrenaline (epinephrine) using a sharp 1½ inch 25 gauge needle. The needle was inserted at the inferotemporal aspect of the lower lid aiming in the direction of the orbital apex. The patient was asked to look straight ahead while the globe was ballotted towards the superi or orbit with the index finger of the non-injecting hand. The needle was positioned in the muscle cone near the posterior pole of the eye. The solution was slowly injected.

**Echographic localisation of corticosteroid after retrobulbar injection**

- Long acting pericocular corticosteroids are commonly used to treat cystoid macular oedema (C MO) resulting from ocu lar inflammation or cataract surgery that does not respond to topical therapy. Drug localisation to the macular area is commonly recommended for optimal therapeutic effect. In post cataract C MO refractory to topical therapy, corticosteroids delivered by retrobulbar and posterior sub-Tenon’s injections are equally effective. Sters given by sub-Tenon’s injection have previously been shown to localise to the macular area. Retrolubular anaesthetic injections have been shown to localise in the intrasaccal space, but not precisely to the macular area. We performed ultrasonography after retrobulbar steroid injection to confirm drug localisation in the macular area.

**CASE REPORT**

Six patients with chronic C MO secondary to sarcoid, idiopathic uveitis, or cataract surgery (Irvine-Gass syndrome) were included in the study. The main inclusion crite ria were presence of a visually significant form of C MO that had either failed topical anti-inflammatory treatment, or was deemed clinically severe enough to warrant systemic or percutaneous injections of corticosteroids primar ily, and willingness to sign informed consent. The main exclusion criteria was refusal to consent to the procedure. Each eye was injected with 1–2 ml of 40 mg/ml triamcinolone acetonide mixed with 0.5 ml of 2% lignocaine (lidocaine) and 0.5 ml of 0.5% adrenaline (epinephrine) using a sharp 1½ inch 25 gauge needle. The needle was inserted at the inferotemporal aspect of the lower lid aiming in the direction of the orbital apex. The patient was asked to look straight ahead while the globe was ballotted towards the superi or orbit with the index finger of the non-injecting hand. Once the needle was positioned in the muscle cone near the posterior pole of the eye, the solution was slowly injected.

B-mode ultrasound was performed within 30 minutes of the retrobulbar injection. After topical proparacaine (proparacaine) was given, a methylcellulose coupling agent was placed on the ultrasonic gel which was then applied directly to the ocular surface. Standard longitudinal, vertical transverse, and axial planes were imaged (Figs 1 and 2).

In 15 of 16 (94%) eyes, the steroid was localised to the macular area defined as the portion of the posterior pole bounded by the optic nerve, major temporal arcades, and 3 mm temporal to the fovea. In eyes where the bolus localised to the macular area, the mean distance between the most anterior aspect of the...
Early wound dehiscence with use of hydroxyapatite orbital implant covered with calf pericardium

Eaton,—Enucleation techniques continue to evolve. While sclera covered hydroxyapatite orbital implants have been quite effective, two major limitations have led us to study other covering materials. One, while there has been no documented human immunodeficiency virus transmission, several patients have expressed concerns about the use of allogeneic sclera because of that issue. Two, in some settings obtaining cadaver donor tissue in a timely manner can be vexing.

Processed calf pericardium has been used in a number of clinical settings as diverse as vascular grafts and neurological surgical patches. Animal ophthalmic data with these materials have shown little untoward effect. While theoretic concerns about prion disease can be raised, no evidence of this problem has been reported from over 90,000 human implantations. While this material is a xenograft that is stored in glutaraldehyde, we are unaware of significant ophthalmic reactions on the basis of either parameter.

I performed a phase I-II trial with commercially available pericardium in 14 patients who underwent enucleations for large intraocular tumours. I compared the results with 126 previous enucleations in similar patients by the same author. Placement of allogeneic scleral wrapped HA implants. When two of these 14 cases developed early, apparently non-infective suture line breakdown (compared with none previously) I stopped the use of this approach.

CASE REPORT
In a phase I-II trial 14 eyes of 14 patients, with large intraocular tumours that were not amenable to eye salvage techniques, underwent enucleation. Three patients had large, unilateral retinoblastomas; 11 had uveal melanomas. In the latter group, eight had primary enucleations and three had their eye removed at relatively long intervals after either brachytherapy or proton radiation. The mean age was 49 years old with a range of 1.3–81 years.

Enucleations were performed in a standard manner, as described elsewhere, using double armed 5–0 polyglycolic and polyactic acids (Vicryl) sutures to imbricate each of the recti muscles. An 18–22 mm HA implant was soaked in a combination of antibiotic-bupivacaine (Marcaine) solution for 5 minutes then covered with a preshaped Oculoguard calf pericardium (Bio-vascular, Inc., St Paul, MN, USA). The open end of the preformed, bag-shaped material was placed posteriorly and was partially closed with interrupted 4–0 polyglycolic and polyactic acid (Vicryl) sutures. A scalp was used to create four windows, each approximately 3 × 5 mm located at the equator. After haemostasis was achieved the recti muscles were each attached to the anterior edge of their respective 3 × 5 mm window. Tenon's layer was then closed with a running 4–0 polyglactic and polyactic acids (Vicryl) circle suture, and overlying interpreted 4–0 polyglycolic and polyactic acids (Vicryl) sutures. The conjunctiva was closed with a running 6–0 plain gut. The retrospective control group was operated on in an identical manner except alcohol preserved allogeneic sclera was used instead of calf pericardium.

Patients who received calf pericardium covered implants have been followed for 7–20 months following surgery. None of these sockets has been drilled for placement of an integrated implant. In two adults we noted breakdown and retraction of the anterior suture line within 1 month of surgery. In neither of the two cases in which breakdown of the suture line in the first month postoperatively was there ocular radiation, pre-existing conditions, or untoward events noted at surgery. In both cases cultures were negative. In the first case, since I had never had this complication in the first month after an enucleation, I assumed that the suture material had broken and took the patient back to the operating room to close the defect. A culture was negative, and I easily resutured the conjunctival edges, but it again broke down 1 week later. In that patient and the second case that presented with a slightly larger defect 2 weeks after enucleation, we removed the anterior face of the calf pericardium that covered the HA implant, and the overlying conjunctival defect was closed with a dermal graft. The first patient has done well. The second case had recurrent breakdown anteriorly so that we removed the implant. No pathogenic organisms were seen.

In the historic control group (126 cases), who had scleral covered HA implants, I had no cases with this type of complication in the first 6 months after surgery.

COMMENT
A large variation in the incidence of post-enucleation complications have been reported. Using the technique outlined above, I have not had an early (<6 months) wound dehiscence or anterior surface breakdown. It is uncertain why we have developed this complication in 14% of cases operated on with bovine pericardium. It is likely that either these patients had a reaction to the xenograft or to the preservative material (although the pericardium is carefully washed in 3% saline solution, bupivacaine (Marcaine) and antibiotics before insertion). In some clinical investigations a higher incidence of early complications with scleral covered hydroxyapatite implants has been reported; these series report wound dehiscence between 3–50%. While that higher incidence has been noted by others, it has not been my experience with a surgical technique that has been basically unchanged for several years.

The mechanism responsible for this early wound dehiscence is uncertain. In an animal study that compared bovine pericardium with homologous sclera there was significantly greater inflammation with the former material; all rabbits that received bovine pericardium wrapped implants had diffuse inflammation in the outer 20% of the material. It is unlikely that our patients had a subclinical infection (cultures were negative and histological studies showed no organisms) although we cannot completely rule out that possibility.

While there are a number of theoretical advantages with the use of calf pericardium instead of allogeneic sclera, the 14% incidence

of a significant complication has truncated my experience with this material.

Supported in part by a grant from the Tumorion Foundation.

DEVORON H CHAR
The Tumorion Eye Foundation, 45 Castro Street, Suite 309, San Francisco, CA 94114, USA
devron@tumori.org

Accepted for publication 14 December 2000

1 Char DH. Ophthalmic oncology. Toronto: BC
       monographs in socket reconstruction. Ophthalmology
       pericardium versus homologous sclera as grafting
       material for hydroxyapatite ocular implants: an animal
4 Holt TA, Phillips J. Bovine spongiform encephalopathy. BMJ
5 Moshefghi DM, Moshefghi AA, Finger PT. Enu-

Wegener's granulomatosis as a cause of cicatrising conjunctivitis

EDITOR,—Wegener's granulomatosis is a mul-

tisystem disorder characterised by the classic triad of necrotising granulomas in the upper respiratory tract and the lung, a variable degree of systemic small vessel vasculitis, and a focal necrotising glomerulonephritis. A limited form of Wegener's granulomatosis, with absence of glomerulonephritis, has been described.1

Ophthalmic complications occur in about 30% of patients with biopsy proved disease.2 Among these orbital pseudotumours ulcerations of the sclera and the cornea are observed most frequently and the histopathological findings have been described.3

Involvement of the conjunctiva and eyelids has also been observed, but progressive scarring of the conjunctiva and its sequelae has not been reported.4

CASE REPORT

A 72 year old man was first seen at our department in November 1997 with bilateral conjunctivitis. His medical history had been uneventful until early 1987, when he developed systemic illness with upper respiratory complaints and renal insufficiency. Wegener's granulomatosis was diagnosed by biopsy of the nasal mucosa and kidney. In 1995 he developed necrotising anterior scleritis and peripheral corneal melting in the left eye. There was complete remission on systemic immunosuppressive therapy.

Since January 1997 the patient has suffered from recurrent bilateral conjunctivitis. He complained about persistent epiphora in the left eye and irritation in both eyes. He was then on local treatment with fusidic acid gel and prednisolone 1% eye drops for 2 weeks. On examination lid margin disease with obstruction of the meibomian glands and obliteration of the left canaliculi was noted. The left upper lid showed inflammatory thickening with haemorrhagic and necrotic ulcerative changes of the tarsal conjunctiva (Fig 1A). In the right eye similar changes were noted; they were, however, much less prominent. Bulbar conjunctiva was unremarkable and there were no other signs of active inflammation in the globe. As there was at that time no evidence of systemically active Wegener's granulomatosis and as cANCA levels were near normal, systemic immunosuppressive treatment was not started again and therapy was restricted to the usual blepharitis regimen (oral tetracycline, lubricating agents, local antibiotics, and steroids).

The patient was referred again in March 1999 after he had suffered several episodes of superficial corneal ulceration in the left eye. On examination the left upper lid was less inflamed than 2 years earlier, but progressive scarring of the tarsus with cicatrical entropion and trichiasis had occurred (Fig 1B). The right upper eyelid showed marked inflammatory thickening, clinically imposing as multiple chalazia. A biopsy from the lateral right upper tarsus disclosed a chronic inflitration with lymphocytes, plasma cells, and occasional histiocytes. Numerous eosinophils but no giant cells were noted. Perivascular inflam-

mation (Fig 2) and areas of active necrosis were only seen in few areas while disorganisation of the tarsus by fibrous tissue was obvious. The analysis of extracorneal tissue and the clinical background, the conjunctival biopsy was regarded as diagnostic.

COMMENT

The current state of knowledge has not recog-

nised Wegener's granulomatosis as a disorder causing cicatrising conjunctivitis.1 The diagnosis of granulomatous conjunctivitis in Wegener's granulomatosis can easily be established in the presence of a history of systemic disease. Conjunctival and eyelid findings, however, may be the presenting symptoms1

Figure 1 (a) Active granulomatous, haemorrhagic inflammation of the left upper tarsus in 1997. (b) Same area 2 years later. Note advanced scarring of the left upper tarsus causing entropion and trichiasis.

Figure 2 Asterisk indicates fibrous hyperplasia in the wall of a small artery as consequence of vasculitis (haematoxylin and eosin, x40).

1 Faucl AS, Wolff SM. Wegener's granulomatosis: studies in eighteen patients and review of the liter-

3 Bulen CL, Liewgang TJ, McDonald TJ, et al. Ocular complications of Wegener's granuloma-

4 Jordan DR, Addison DJ. Wegener's granuloma-

5 Bernauer W, Durr KG, Elder MJ, eds. Cicatrizing conjunctivitis. Developments in Ophthalmol-


An unusual presentation of diabetic neuropathy

EDITOR,—Diabetic neuropathy can present in numerous forms; as symmetrical sensory polyneuropathy, mononeuropathy, or as an autonomic neuropathy. The earliest functional change in diabetic nerves is delayed conduc-

tion velocity, the earliest histological change is segmental demyelination due to damage of Schwann cells. We report an uncommon but important presentation, which can easily be overlooked on clinical examination.

CASE REPORT

A 27 year old woman was referred to Moorfields Eye Hospital complaining of bilat-

erally red and irritable eyes accompanied by a previously unrecorded 10 year history of control of her diabetes mellitus with insulin. Her visual acuity was recorded at 6/60 right, 6/24 left unaided. It was also noted that she had complete corneal anaesthesia in both eyes. Basic neurological examination was oth-

erwise normal.

On examination she was noted to have bilateral conical erosions. She had a reduced blink rate and peripheral corneal thinning. Her visual acuity was recorded at 6/60 right, 6/24 left unaide. It was also noted that she had complete corneal anaesthesia in both eyes. Basic neurological examination was oth-

erwise normal.

The patient had the typical appearances of a neurotrophic epithelium. She was started on hypromellose 1% eye drops and chloramphenicol 1% eye drops four times daily, daily, both preserved free to stabilise her epithelium, and this improved her symptoms and vision. Further progress was obtained with therapeu-

tic contact lenses, and her visual acuity improved to 6/18 in both eyes. Because of her
Corneal ulceration.

Factors as a treatment for neurotrophic potential to use topical neurotrophic growth when examined in a study of 130 patients

Patients had a degree of corneal hypoaesthesia, which can often be overlooked. Forty-five per cent of diabetic patients, and vitamin deficiencies are important causes due to hypoplasia of the ophthalmic division of the trigeminal nerve. Systemic disease such as diabetes, myotonic dystrophy, scleroderma, and vitamin deficiencies are important causes of corneal anaesthesia, which can often be overlooked. Forty-five per cent of diabetic patients had a degree of corneal hypoaesthesia when examined in a study of 130 patients published by Osman et al. There is little or no relation between the age of a diabetic patient and the observed decrease in corneal sensitivity. However, corneal sensitivity thresholds do rise with increased duration of diabetes.

It has been suggested that diabetic peripheral neuropathy was due to occlusive vascular disease and nerve infarctions. More recent evidence suggests that common symmetrical distal polyneuropathy is due to segmental demyelination with associated or secondary axonal degeneration.

Recent studies show that there may be a potential to use topical neurotrophic growth factors to treat neurotrophic corneal ulceration. In a study of 14 eyes Lambiasa et al. treated neurotrophic corneal ulcers with topical nerve growth factor for 2 weeks. Corneal healing began within 2–14 days and all patients had complete healing of their ulcers after 10 days to 6 weeks. Corneal anaesthesia may often be overlooked unless it is profound. It can be tested with cotton wisp or an anesthesiometer. It is important to test the corneal sensation subjectively and objectively and also to test all four quadrants of the cornea.

This case raises three important points:

- Chronically irritated eyes should have their corneal sensation tested. Corneal anaesthesia is easily overlooked by non-ophthalmologists and ophthalmologists alike, and the anaesthetic cornea represents a real risk of profound visual loss from trauma and infection.
- Reduced corneal sensation can be a presenting feature of diabetic neuropathy. This woman had no other symptoms or signs of neuropathy apart from her corneal anaesthesia. If a diabetic develops a red or irritable eye, corneal sensation should be tested.
- There is some promise for the future in that neurotrophic corneal ulceration may potentially be treated by the use of topical neurotrophic growth factors. The research into this project continues and is currently not in clinical practice.

**COMMENT**

Corneal anaesthesia can be physiological or pathological. Corneal sensation decreases with age, and is lower in females, especially premenstrually. Contact lens wear, and infection by herpetic zoster and simplex, oedema and surgery will also reduce sensation. Congenital causes of corneal anaesthesia include corneal dystrophy and Riley-Day syndrome, and congenital corneal anaesthesia without an associated syndrome, which is presumed to be due to hypoplasia of the ophthalmic division of the trigeminal nerve. Systemic disease such as diabetes, myotonic dystrophy, scleroderma, and vitamin deficiencies are important causes of corneal anaesthesia, which can often be overlooked. Forty-five per cent of diabetic patients had a degree of corneal hypoaesthesia when examined in a study of 130 patients published by Osman et al. There is little or no relation between the age of a diabetic patient and the observed decrease in corneal sensitivity. However, corneal sensitivity thresholds do rise with increased duration of diabetes.

It has been suggested that diabetic peripheral neuropathy was due to occlusive vascular disease and nerve infarctions. More recent evidence suggests that common symmetrical distal polyneuropathy is due to segmental demyelination with associated or secondary axonal degeneration.

Recent studies show that there may be a potential to use topical neurotrophic growth factors to treat neurotrophic corneal ulceration. In a study of 14 eyes Lambiasa et al. treated neurotrophic corneal ulcers with topical nerve growth factor for 2 weeks. Corneal healing began within 2–14 days and all patients had complete healing of their ulcers after 10 days to 6 weeks. Corneal anaesthesia may often be overlooked unless it is profound. It can be tested with cotton wisp or an anesthesiometer. It is important to test the corneal sensation subjectively and objectively and also to test all four quadrants of the cornea.

This case raises three important points:

- Chronically irritated eyes should have their corneal sensation tested. Corneal anaesthesia is easily overlooked by non-ophthalmologists and ophthalmologists alike, and the anaesthetic cornea represents a real risk of profound visual loss from trauma and infection.
- Reduced corneal sensation can be a presenting feature of diabetic neuropathy. This woman had no other symptoms or signs of neuropathy apart from her corneal anaesthesia. If a diabetic develops a red or irritable eye, corneal sensation should be tested.
- There is some promise for the future in that neurotrophic corneal ulceration may potentially be treated by the use of topical neurotrophic growth factors. The research into this project continues and is currently not in clinical practice.

**Bilateral acute retinal necrosis and herpes simplex type 2 encephalitis in a neonate**

Editor,—Acute retinal necrosis (ARN) is a rapidly progressing, sometimes devastating, retinitis associated with the herpes virus family. First described in 1971,1 it is diagnosed by the clinical triad of progressive peripheral retinal necrosis, occlusive vasculopathy, and vitreous inflammation.2 The association of herpetic encephalitis with ARN has been described in adults.1,3 Herpes simplex virus type 2 (HSV-2) has also been recognised as one of the causative agents of the ARN syndrome, particularly in Japan. It has been suggested that ARN in patients less than 25 years of age is likely to be caused by HSV-2.4 We present a case of bilateral ARN (BARN) in a neonate with HSV-2 encephalitis.

**CASE REPORT**

A 25 day old infant presented with a 4 day history of lethargy, poor feeding, and coughing. Examination revealed an injected, blished pharynx and a solitary red skin lesion on the left upper arm accompanied by a cluster of tender pharynx and a solitary red skin lesion on the left upper arm. A sample of cerebrospinal fluid (CSF), obtained by lumbar puncture, was sent for polymerase chain reaction (PCR) analysis. Both specimens were non-diagnostic band on PCR. Histology, including electron microscopy, of the retinal biopsy revealed a real risk of profound visual loss from trauma and infection.

1. Neurontin is an oral aciclovir that can be used to demarcate the interface between necrotic and healthy retina.

**COMMENT**

Neonatal HSV infection is usually symptomatic and has a high mortality. Three quarters of cases are due to HSV-2 and this is most commonly acquired from the maternal genital tract lesion during delivery. The maternal HSV titre in this case suggest that the mother acquired a primary infection during the third trimester. A diagnosis of encephalitis was confirmed by the CT scan appearance and a PCR positive for HSV-2 in the CSF. The retinitis was first observed only 6 days after the onset of the systemic symptoms and progressed significantly despite intravenous administration of aciclovir. This treatment was continued for several weeks and was then followed by oral therapy. The fact that HSV was not identified from the vitreous or retinal biopsy may be attributable to the prolonged antiviral treatment.

HSV encephalitis is a severe infection, especially in the neonate, that carries a potential risk of significant ocular involvement. This case highlights the importance of early diagnosis and active management. Like ARN in adults, this may include the need for prophylactic laser retinal photocoagulation to prevent retinal detachment and, should this fail, pars plana vitrectomy with silicone oil tamponade.
Surgical excision, autolimbal transplantation, and mitomycin C in the treatment of conjunctival and corneal intraepithelial neoplasia

EDITOR,—Conjunctival and corneal intraepithelial neoplasia (CIN) are uncommon lesions of low malignant potential.1 Surgical excision is the standard treatment for this condition. However, owing to the poorly defined borders of these lesions, recurrence rates following surgical excision can be as high as 53%.2 Adjunctive therapy including cryotherapy,3 radiotherapy,4 immunotherapy,5 and topical alcohol and urea have been used to treat the condition. Many of these procedures induce limbal stem cell failure with consequent corneal epithelial problems, requiring (auto) stem cell transplantation. Topical cytotoxic agents like 5-fluorouracil and mitomycin C have been used successfully in the treatment of CIN.6 However, inhibition of limbal stem cell division with mitomycin C is thought to notably impair physiological corneal epithelial replacement.7 We report the successful use of prolonged mitomycin C after autolimbal transplantation in the treatment of recurrent CIN.

CASE REPORT
A 37 year old white woman presented in February 1995 with a 6 month history of a fleshy white lesion in the corner of her right eye. In the past she had experienced intermittent episodes of bilateral sore, red eyes. Her visual acuities were 6/18 with pinhole in the right eye and 6/5 in the left eye. Ocular examination revealed a whitish elevated lesion on the right limbal conjunctiva from 7 to 11 o’clock extending almost to the central cornea (Fig 1A).

The patient underwent excision biopsy of the lesion. Intraoperatively the exposed bed of the lesion was treated with absolute alcohol and the conjunctival edge with two cycles of cryotherapy. Postoperatively, a bandage contact lens was inserted and she was treated with topical preservative-free antibiotics and steroids. One month later the corneal and conjunctival epithelium had healed completely and vision improved to 6/12. Histology confirmed the lesion to be conjunctival and corneal intraepithelial neoplasia (Fig 1B).

Two months postoperatively, she developed a recurrence in the form of two central, abnorrmal areas of corneal epithelium. These were treated by scraping and application of absolute alcohol to the bed of the lesion. Histology identified these lesions to be severely dysplastic corneal epithelial cells. Subsequently she developed right limbal stem cell failure resulting in recurrent episodes of filamentary and punctate keratitis and a reduction of visual acuity to 6/18. Histology of corneal scrapes showed epithelial cells and goblet cells. In February 1998 she underwent a right autologous limbal transplant and vision improved to 6/9.

Two months later she had a recurrence of CIN involving one third of the cornea (Fig 1C). This was treated with four cycles of 0.04% mitomycin C applied four times a day, for 10 days at a time. The tumour regressed completely in 3 months. Twenty months later she remains asymptomatic with a clear cornea (Fig 1D).

COMMENT
Mitomycin C is a cytotoxic alkylating agent which inhibits DNA synthesis and is, therefore, most effective against rapidly dividing cells. While it has been used to treat recurrences of CIN, there have been concerns about the effects of mitomycin C on the limbal stem cells and the integrity of the corneal epithelium.8 In our patient the grafted limbal stem cells and corneal epithelium remained healthy in spite of the significant dose of mitomycin C required to treat her recurrent CIN.

To the best of our knowledge this is the first reported case of topical mitomycin C used successfully against CIN after autolimbal transplant, despite the prolonged duration of application (40 days).

The authors would like to thank Miss April Powell-Richards and Professor J Lowie for their help with the illustrations.

ANNIE JOSEPH
KOURESH SABRI
HARMINDER S DUA
Department of Ophthalmology, University Hospital, Queen’s Medical Centre, Nottingham NG7 2UH, UK
Correspondence to: Professor HS Dua, Department of Ophthalmology, B Floor, Eye, Ear, Nose and Throat Centre, University Hospital, Nottingham NG7 2UH, UK

harminderd.aa@nottingham.ac.uk
Accepted for publication 24 January 2001


Bilateral granulomatous uveitis in association with common variable immunodeficiency

EDITOR,—We report a case of bilateral granulomatous uveitis, which prompted extensive diagnostic review in a 20 year old woman with a long history of recurrent infection and idiopathic thrombocytopenia. Investigations allowed the definitive diagnosis of common variable immunodeficiency with granulomas (granulomatous antibody deficiency syndrome).9 To our knowledge this is the first reported case of granulomatous uveitis in

Figure 1A Pretreatment view of right eye showing conjunctival/corneal intraepithelial neoplasia (CIN). (B) Photomicrograph of the initial biopsy showing the features of CIN (stain haematoxylin and eosin, original magnification, ×100). (C) Recurrence of CIN after autolimb transplantation. (D) The lesion has not recurred 20 months after mitomycin C therapy. Arrows show the two areas of autolimbal transplantation.

www.bjophthalmol.com
CASE REPORT
A 20 year old woman presented with sudden onset blurred vision. Examination revealed a bilateral granulomatous uveitis with mutton-fat keratic precipitates and anterior chamber cells. Two weeks later she developed bilateral optic disc swelling with multifocal areas of choroidal pallor in her left eye (Fig 1). There was no viritis or evidence of retinal vascular changes. Her uveitis settled on topical steroids and she maintained vision of 6/6 in the right eye and 6/9 in the left. The working diagnosis was sarcoidosis.

However, serum angiotensin converting enzyme (ACE) was not elevated and magnetic resonance imaging (MRI) showed no evidence of neurosarcoid. Plain chest films and high resolution computed tomography of the thorax revealed bilateral hilar and paratracheal lymphadenopathy, with air space shadowing and ill defined nodular opacities in both lower zones. Bronchial biopsies, obtained at fibre-optic bronchoscopy, showed inflammation of the bronchial epithelium consistent with bronchial pneumonia. No granulomata were seen.

As a child she had suffered from recurrent chest infections, with severe neutropenia and thrombocytopenia. By 6 years of age she had developed splenomegaly and widespread lymph node enlargement. Kveim and Mantoux test were both negative. Investigations for lymphoma over several years were negative. At 13 she underwent splenectomy for idiopathic thrombocytopenia. No definitive diagnosis was established for her in childhood.

She suffered an episode of parotitis and vomiting, accompanied by fever and hepatomegaly, requiring intravenous antibiotics. This precipitated a drug induced hepatitis with ascites, which became infected, resulting in a chronic, low grade peritonitis. Epstein-Barr virus, cytomegalovirus, and parvovirus serology was normal. Histological review showed that the spleen had little white pulp and few germinal centres (Fig 2), while lymph nodes showed multiple, small, non-caseating granulomata and few germinal centres (Fig 2). Immunological investigation showed all immunoglobulin levels were reduced, with IgG 0.1 g/l (normal 5.4–16.1 g/l), IgA <0.1 g/l (normal 0.8–2.8 g/l), and IgM 1.0 g/l (normal 0.5–1.9 g/l). Lymphocyte subclasses and bone marrow biopsy were normal.

The diagnosis of common variable immunodeficiency syndrome (CVIS) with granulomas was made. Her exacerbations of idiopathic thrombocytopenia responded to immunoglobulin therapy.

COMMENT
CVIS is a primary immunodeficiency characterised by decreased or absent levels of immunoglobulins. Patients suffer from recurrent bacterial infections and respiratory failure is the principal cause of death. Autoimmune disease is seen in approximately 10% of cases, especially thrombocytopenia, haemolytic anaemia, and rheumatoid arthritis; 25% have splenomegaly and approximately one third have non-caseating granulomata in sites such as the liver, lungs, spleen, and lymph nodes. This variant is called granulomatous antibody deficiency (GAD). A sarcoid-like syndrome may be seen in 7.5% of patients.

To our knowledge this is the first reported case of bilateral granulomatous uveitis in association with GAD. As in sarcoidosis, serum ACE may be elevated if the granuloma burden is high and a Kveim test may be positive. The diagnosis of GAD hinges on the presence of hypogammaglobulinaemia, while in sarcoidosis immunoglobulin levels are normal or raised.

Granulomatous uveitis is often an indicator of systemic disease. When there is a history of recurrent infection or of autoimmune disease, immunoglobulin levels should be measured to exclude the possibility of a treatable immunodeficiency.
CASE REPORT
A 77 year old woman with high myopia and left aphakia underwent uncomplicated elective phacoemulsification surgery of the right eye, and was noted to have coexisting orbital cellulitis.

There was a general assumption that orbital cellulitis is an infectious consequence of endophthalmitis, where the orbit was infected with the causative pathogen. On the other hand, orbital cellulitis could simply be an inflammatory response to the severe infection of the globe. The patient we described presented with coexisting orbital cellulitis and endophthalmitis, probably resulting from simultaneous inoculation of the infecting organism into orbital tissues and the eye from the conjunctiva. This is supported by the findings of peri-orbital soft tissue swelling on the CT scan. In addition, the degree of orbital involvement could simply reflect the virulence of the particular organism of the patient’s eye, where the orbit was infected with a pathogen, and minor concurrent endophthalmitis could have occurred.

The latest issue of Community Eye Health—Medicine—Millennium Ultrasound Course Series
A course entitled “Obstetrical and Gynecological Ultrasound” will be held in New York City, NY, on 24–26 August 2001. Further details: Stacey Bessling, Public Relations Coordinator, AIUM, 14750 Switzer Lane, Suite 100, Laurel, MD 20707-5906, USA (tel: 301-498-4100; email: sbessling@aium.org).

American Institute of Ultrasound in Medicine—2nd Interdisciplinary Symposium on the Treatment of Autoimmune Disorders 2001
The 2nd Interdisciplinary Symposium on the Treatment of Autoimmune Disorders 2001 will take place on 7–9 June 2001 at the University Hospital, University of Kiel, Kiel, Germany. Further details: Prof Dr Med Michael Sticherling, Department of Dermatology, University of Kiel, Schittenhelmstrasse 7, D-24105 Kiel, Germany (tel: +49-431 971 1512; fax: +49-431 971 1611; email: m.sticherling@dermatology.uni-kiel.de).

European Intensive Program of Disease and Imaging of the Fundus
The European Intensive Program of Disease and Imaging of the Fundus under the auspices of the European Program Socrates will be held on 7–8 June 2001 at the Clinic Ophthalmologie, 40 avenue de Verdun, 94010 Créteil, France. Further details: Béatrice Rousseau (tel: (33 1) 45 17 52 22; fax: (33 1) 45 17 52 66).

NOTICES
National prevention of blindness programmes and Vision 2020
The latest issue of Community Eye Health (36) discusses national prevention of blindness programmes. For further information please contact Community Eye Health, International Centre for Eye Health, Institute of Ophthalmology, 11–43 Bath Street, London EC1V 9EL. (Tel: (+44) (0) 20-7608 6909/6910/6923; fax: (+44) (0) 7250 3207; email: ceh@group.bmj.com; website: www.ophthalmology.com) Annual subscription £25. Free to workers in developing countries.

Second Sight
Second Sight, a UK based charity whose aims are to eliminate the backlog of cataract blind in India by the year 2020 and to establish strong links between Indian and British ophthalmologists, will be sending volunteer surgeons to India early in 2001. Details can be found at the charity website at www.second-sight.org.uk or by contacting Dr Lucy Mathen (email address lucymathen@yahoo.com).

indicated that it will designate the 14th World Congress of ISLSM as its society’s co-sponsoring meeting. A pre-conference course and separate sessions in ophthalmology will be held as a part of this international meeting. Further details: Dr B Krishna Rau, President, 14th World Congress of the International Society for Laser Surgery and Medicine, Department of Surgery, D2 Ward, Sri Ramachandra Medical College and Research Institute, Porur, Chennai - 600 116, India (tel: 91-44-4765856, 4768027-28, 8527776, 8594804; fax: 91-44-8594578, 4767008; email: krishnar@giamsmd01.vsnl.net.in and website: www.medindia.net/islsm2001).

31st Cambridge Ophthalmological Symposium
The 31st Cambridge Ophthalmological Symposium will be held 3–5 September 2001 at St John’s College Cambridge. The subject is Retinal Detachment. Further details: COS Secretariat, Cambridge Conferences, The Lawn, 33 Church Street, Great Shelford, Cambridge CB2 5EL, UK (tel: 01223 847464; fax: 01223 847465; email: b.ashworth@easynet.co.uk).

1st Asia Pacific Forum on Quality Improvement in Health Care
The 1st Asia Pacific Forum on Quality Improvement in Health Care will be held from 19–21 September 2001 in Sydney, Australia.

Presented by the BMJ Publishing Group (London, UK) and Institute for Healthcare Improvement (Boston, USA), with the support of the Commonwealth Department of Health and Aged Care (Australia), Safety and Quality Council (Australia), NSW Health (Australia) and Ministry of Health (New Zealand). Further details: quality@bma.org.uk; fax +44 (0) 7383 6869.

41st St Andrew’s Day Festival Symposium on Therapeutics
The 41st St Andrew’s Day Festival Symposium on Therapeutics will be held on 6–7 December 2001 at the Royal College of Physicians of Edinburgh. Further details: Ms Eileen Strawn, Symposium Co-ordinator (tel: 0131 225 7324; fax: 0131 220 4393; email: e.strawn@rcpe.ac.uk; website: www.rcpe.ac.uk).

4th International Conference on the Adjuvant Therapy of Malignant Melanoma
The 4th International Conference on the adjuvant therapy of malignant melanoma will be held at The Royal College of Physicians, London on 15–16 March 2002. Further details: Conference Secretariat, CCI Ltd, 2 Palmerston Court, Palmerston Way, London SW8 4AJ, UK (tel: +44 (0) 20 7720 0660; fax: +44 (0) 20 7720 7177; email: melanoma@confcomm.co.uk; website: www.confcomm.co.uk/Melanoma).

XXIXth International Congress of Ophthalmology
The XXIXth International Congress of Ophthalmology will be held on 21–25 April 2002 in Sydney, Australia. Further details: Congress Secretariat, C/- ICMS Australia Pty Ltd, GPO Box 2609, Sydney, NSW 2001, Australia (tel: +61 2 9241 1478; fax: +61 2 9251 3552; email: ophthal@icmsaust.com.au; website: www.ophthalmology.aust.com).

International Society for Behçet’s Disease
The International Society for Behçet’s Disease was inaugurated at the 9th International Congress on Behçet’s Disease. Professor Shigeaki Ohno represents the ophthalmology division (Department of Ophthalmology and Visual Sciences, Hokkaido University Graduate School of Medicine, Sapporo, Japan: tel: +81-11-716-1161 (ext 5944); fax +81-11-736-0952; email: sohno@med.hokudai.ac.jp). The 10th International Congress on Behçet’s Disease will be held in Berlin 27–29 June 2002. Further details: Professor Ch Zouboulis (email: zoubbere@zedat.fu-berlin.de).
Bilateral acute retinal necrosis and herpes simplex type 2 encephalitis in a neonate

ANDRÉS KYCHENTHAL, ANDREW COOMBES, JOHN GREENWOOD, CARLOS PAVESIO and GEORGE W AYLWARD

Br J Ophthalmol 2001 85: 625
doi: 10.1136/bjo.85.5.625f

Updated information and services can be found at:
http://bjo.bmj.com/content/85/5/625.8

These include:

References
This article cites 7 articles, 1 of which you can access for free at:
http://bjo.bmj.com/content/85/5/625.8#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/